Mixed Digital Intervention Increases HIV Prevention Adherence in Young People
By Lori Solomon HealthDay Reporter
TUESDAY, March 5, 2024 -- A synergistic effect is seen for multimodal strategies to improve uptake of and adherence to HIV prevention among young people at risk for acquisition, according to a study published in the March issue of The Lancet Digital Health.
Dallas Swendeman, Ph.D., from the University of California, Los Angeles, and colleagues assessed the efficacy of automated text messaging and monitoring (AMMI), online peer support, and strengths-based telehealth coaching to improve uptake of and adherence to preexposure prophylaxis (PrEP), condom use, and postexposure prophylaxis among 895 young people (aged 16 to 24 years) at risk for HIV acquisition.
The researchers found that at baseline, two-thirds of participants reported anal sex without a condom in the previous 12 months. PrEP use at baseline (11 percent) was comparable to young people nationally but increased at four months to 15 percent and continued to increase in the AMMI plus peer support and coaching group (odds ratio, 2.31 versus AMMI control). Interventions had no effect on condom use, postexposure prophylaxis use (i.e., prescription or adherence), PrEP adherence, or sexual partner numbers.
"Results are consistent with hypothesized synergistic intervention effects of evidence-based functions of informational, motivational, and reminder messaging; peer support for HIV prevention; and strengths-based, goal-focused, and problem-solving telehealth coaching delivered by near-peer paraprofessionals," the authors write.
Several authors disclosed consulting fees to relevant organizations.
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2024 HealthDay. All rights reserved.
Posted March 2024
Read this next
Limited Progress on QoL Goals Reported for Persons With HIV Aged 50 Years and Older
FRIDAY, Sept. 13, 2024 -- For persons diagnosed with HIV (PWH) aged 50 years and older, progress on quality of life (QoL) goals is limited, according to a study published online...
Long-Acting Cabotegravir Well Tolerated in Pregnant Women
THURSDAY, Aug. 8, 2024 -- Long-acting injectable cabotegravir (CAB-LA) appears to be well tolerated in pregnant women, according to a study presented at AIDS 2024, the 25th...
Hep C Reinfection Observed in HIV-Positive Men Who Have Sex With Men
THURSDAY, Aug. 8, 2024 -- The incidence rate of hepatitis C virus (HCV) reinfection was 4.7 per 100 person-years among men who have sex with men (MSM) with HIV who cleared HCV...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.